Telmisartan inhibits human urological cancer cell growth through early apoptosis

• Published in: Experimental and therapeutic medicine Vol. 1; no. 2; pp. 301 - 306
• Main Authors: MATSUYAMA, MASAHIDE, FUNAO, KIYOAKI, KURATSUKURI, KATSUYUKI, TANAKA, TOMOAKI, KAWAHITO, YUTAKA, SANO, HAJIME, CHARGUI, JAMEL, TOURAINE, JEAN-LOUIS, YOSHIMURA, NORIO, YOSHIMURA, RIKIO
• Format: Journal Article
• Language: English
• Published: Greece D.A. Spandidos 01.03.2010
• Subjects: angiotensin II receptor blocker; apoptosis; telmisartan; urological cancer
• ISSN: 1792-0981; 1792-1015
• DOI: 10.3892/etm_00000046

Angiotensin II receptor blockers (ARBs) are widely used as hypertensive therapeutic agents. In addition, studies have provided evidence that ARBs have the potential to inhibit the growth of several types of cancer cells. It was reported that telmisartan (a type of ARB) has peroxisome proliferator-activated receptor (PPAR)-γ activation activity. We previously reported that the PPAR-γ ligand induces growth arrest in human urological cancer cells through apoptosis. In this study, we evaluated the effects of telmisartan and other ARBs on cell proliferation in renal cell carcinoma (RCC), bladder cancer (BC), prostate cancer (PC) and testicular cancer (TC) cell lines. The inhibitory effects of telmisartan and other ARBs (candesartan, valsartan, irbesartan and losartan) on the growth of the RCC, BC, PC and TC cell lines was investigated using an MTT assay. Flow cytometry and Hoechst staining were used to determine whether the ARBs induced apoptosis. Telmisartan caused marked growth inhibition in the urological cancer cells in a dose- and time-dependent manner. Urological cancer cells treated with 100 μM telmisartan underwent early apoptosis and DNA fragmentation. However, the other ARBs had no effect on cell proliferation in any of the urological cancer cell lines. Telmisartan may mediate potent anti-proliferative effects in urological cancer cells through PPAR-γ. Thus, telmisartan is a potent target for the prevention and treatment of human urological cancer.